Meanwhile, Western blotting suggested that the combination of these drugs could promote AML cell cycle arrest at G1/G0 phase by promoting the expression of p16 and p21, and reducing the expression of CDK4 and CDK2 (Fig. 4E–F). Here, CDK4 is linked to acute myeloid leukemia.